Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.
We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.
Thank you for your interest in ITM’s symposium“Actinium-225 Targeted Radionuclide Therapy – Current Perspective and Future Outlooks” from the Theranostic World Congres 2022.
A recording of the symposium and the ensuing discussion is available to Healthcare Professionals here: View full recording
The symposium titled, “Actinium-225 Targeted Radionuclide Therapy – Current Perspective and Future Outlooks” will take place on June 25, from 11:30 am to 12:55 pm CET. Participants can attend in person or join via live stream, which will be available on the TWC website ahead of the congress.
The event will feature expert speakers, Prof. Matthias Eiber, Associate Professor, Clinic and Polyclinic for Nuclear Medicine, Klinikum rechts der Isar, TU Munich, Prof. Katharina Lückerath, Preclinical Theranostics, Clinic for Nuclear Medicine, University Hospital Essen and Neil Quigley, Global Product Manager at ITM.
An Evaluation of Current and Prospective 225Ac Production Methods
Neil Quigley, Global Product Manager, ITM, Garching / Munich
225Ac-PSMA for the Treatment of Prostate Cancer – Preclinical Experience
Prof. Katharina Lückerath, University Hospital Essen
Current Clinical Experience for 225Ac-PSMA in mCRPC
Prof. Matthias Eiber, Klinikum rechts der Isar, Technical University of Munich